Evaluating The Benefit-Risk Profile Of Fexofenadine By Using Multi-criteria Decision Analysis Model

Objective :To assess the benefit-risk of single medicine by using Multi-Criteria Decision Analysis(MCDA)Model. To evaluate the benefit-risk profile of fexofenadine for treating allergic rhinitis, so as to provide guidance for clinical use. Method:MEDLINE, EMBASE, and the Cochrane library were searched for randomized controlled trials and other open-label trials about fexofenadine treating allergic rhinitis. Extracted all benefit-risk criteria from original articles, a value tree was constructed that displayed evaluation criteria for benefit and risk. Assigned Weights by using Swing weighting, determined score for each criteria on 0-100 scale, then combined weights and score, calculated the total benefit-risk value by using multiple criteria decision analysis. Result:A total of 116 potentially relevant articles were identified by the search, 25 satisfied the inclusion criteria. The final value tree had 2 branches representing favorable and unfavorable effects. Favorable effects criteria included improvement of symptoms, efficacy evaluation, health activities, Unfavorable effects included total adverse events and treat discontinuation due to AEs. For favorable effects, the symptom improvement had the highest weight(100), followed by efficacy evaluation(80)and health activities(80). For unfavorable effects, treat discontinuation due to AEs had the highest weight, followed by drug-associated adverse events. After a MCDA analysis, the total value of fexfenadine180 mg, fexofenadine 120 mg and placebo was 20, 21 and 11, respectively. Conclusion:The benefit risk value of fexofenadine 120 mg was close to 180 mg in treating allergic rhinitis, the value of benefit was greater than risk, and the total value was greater than placebo. fexofenadine was safe in treating allergic rhinitis.